Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RIGL
Strong BuyFull HouseFLAGRigel Pharmaceuticals, Inc. · Healthcare · United States · $868M · Avg Vol: $14M/d
Passes the eligibility phase with strong growth/quality scores. However, the concurrent signal of insider selling, despite the small volume and share buyback program, necessitates a flag to verify the management's capital allocation strategy.
COMPANY DESCRIPTION
Rigel Pharmaceuticals, Inc. is a commercial-stage biotechnology company dedicated to the discovery, development, and provision of novel small molecule drugs for serious diseases. Its approved product, TAVALISSE, is used to treat chronic immune thrombocytopenia, showcasing its expertise in immunology. Rigel maintains a competitive edge through its proprietary R&D platform and pipeline targeting various immunological and oncological conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 120.2M | 116.9M | 179.3M | 294.3M | 34.8% | 276.8M | 305.7M | 372.8M | 12.6% |
| EPS | -3.40 | -1.44 | 0.99 | 20.40 | 1960.6% | 16.89 | 11.24 | 15.67 | -12.4% |
| Shares | 17.3M | 17.5M | 17.7M | 18.3M | +5.6% | 18.7M | — | — | — |
| Debt | 41.6M | 60.6M | 60.0M | 53.3M | 8.7% | 40.0M | — | — | — |
| Equity | -13.6M | -28.6M | 3.3M | 391.5M | 11806.3% | — | — | — | — |
| Op CF | -73.8M | -5.7M | 31.5M | 75.7M | 140.4% | 79.4M | — | — | — |
| Inv CF | 72.8M | -4.3M | 4.1M | -92.4M | — | — | — | — | — |
| Fin CF | 6.5M | 18.4M | -11.6M | 0.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RIGL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RIGL | Rigel Pharmaceuticals, Inc.(you) | $868M | 99 | Strong Buy |
| CRMD | CorMedix Inc. | $647M | 98 | Strong Buy |
| PBYI | Puma Biotechnology, Inc. | $468M | 98 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $687M | 91 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $1.0B | 84 | Strong Buy |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | 100 | Strong Buy |
| QTTB | Q32 Bio Inc. | $447M | 89 | Strong Buy |
| TBPH | Theravance Biopharma, Inc. | $885M | 76 | Buy |
| 1521.HK | Frontage Holdings Corporation | $310M | 93 | Strong Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%